TORONTO, Aug. 14,
2023 /PRNewswire/ - Auxly Cannabis Group
Inc. (TSX: XLY) (OTCQB: CBWTF) ("Auxly" or the
"Company") today released its financial results for the
three and six months ended June 30,
2023. These filings and additional information regarding
Auxly are available for review on SEDAR at www.sedar.com. All
amounts are Canadian dollars except common shares ("Shares")
and per Share amounts.
Q2 2023 Highlights and Subsequent Events
- Total net revenues of $22.0
million in Q2 2023, a decrease of $2.0 million or 8% from the previous quarter and
a decrease of $5.3 million or 20%
compared to the same period in 2022;
- SG&A declined by $1.3 million
or 13% from the previous quarter and $4.1
million or 32% from the same period in 2022 as the Company
continues to focus its efforts on reducing costs;
- Adjusted EBITDA was negative $1.1
million, an improvement of $2.9
million as compared to the same period last year;
- Retained the #5 LP position in Canada with a 5.2% share of market and
continued to improve sales in the pre-roll segment, one of the
fastest growing product categories, finishing the quarter with 3.4%
share of market up from 2.9% in the previous
quarter1;
- Back Forty Wedding Pie grew to become the #1 non-infused
pre-roll SKU nationally in the quarter1;
- Successfully streamlined operations by transitioning all
remaining dried flower and pre-roll cannabis product manufacturing,
processing and distribution activities to Auxly Leamington;
and
- Further strengthened the Company's balance sheet by entering
into an agreement with strategic partner Imperial Brands to extend
the maturity date of the Imperial Brands convertible debenture by
two years from September 25, 2024 to
September 25, 2026.
|
_____________________________________
1 Data provided by HiFyre IQ as at July 31,
2023
|
Financial Highlights
For the three months
ended:
|
|
June
30,
|
June 30,
|
|
|
|
(000's)
|
|
2023
|
2022
|
Change
|
|
Change
|
Total net
revenues
|
|
21,990
|
27,335
|
(5,345)
|
|
-20 %
|
Net
income/(loss)
|
|
(12,863)
|
(14,289)
|
1,426
|
|
10 %
|
Adjusted
EBITDA*
|
|
(1,078)
|
(3,995)
|
2,917
|
|
73 %
|
Weighted average shares
outstanding
|
|
1,002,014,308
|
888,266,729
|
113,747,579
|
|
13 %
|
For the six months
ended:
|
|
June
30,
|
June 30,
|
|
|
|
(000's)
|
|
2023
|
2022
|
Change
|
|
Change
|
Total net
revenues
|
|
45,958
|
49,961
|
(4,003)
|
|
-8 %
|
Net
income/(loss)
|
|
(23,112)
|
(54,135)
|
31,023
|
|
57 %
|
Adjusted
EBITDA*
|
|
(940)
|
(10,319)
|
9,379
|
|
91 %
|
Weighted average shares
outstanding
|
|
978,146,905
|
875,843,490
|
102,303,415
|
|
12 %
|
As at:
|
|
June
30,
|
December 31,
|
|
|
(000's)
|
|
2023
|
2022
|
Change
|
Change
|
Cash and
equivalents
|
|
$
8,557
|
$
14,636
|
$
(6,079)
|
-42 %
|
Total assets
|
|
$
316,890
|
$
331,820
|
$
(14,930)
|
-4 %
|
Debt**
|
|
$
174,201
|
$
174,475
|
$
(274)
|
0 %
|
|
*Adjusted EBITDA is a
Non-IFRS financial measure. Refer to the Non-GAAP Measures.
**Debt is a supplementary financial measure. Refer to the Non-GAAP
Measures.
|
Results of Operations
For the periods
ended:
|
|
Three months June
30,
|
|
Six months June
30,
|
(000's)
|
|
2023
|
2022
|
|
2023
|
2022
|
Revenues
|
|
|
|
|
|
|
Revenue from sales of
cannabis products
|
|
$
34,514
|
$
40,088
|
|
$
72,058
|
$
73,292
|
Excise taxes
|
|
(12,524)
|
(12,753)
|
|
(26,100)
|
(23,331)
|
Total net
revenues
|
|
21,990
|
27,335
|
|
45,958
|
49,961
|
|
|
|
|
|
|
|
Costs of
sales
|
|
|
|
|
|
|
Costs of finished
cannabis inventory sold
|
|
16,035
|
20,574
|
|
31,060
|
38,096
|
Biological asset
impairment
|
|
-
|
-
|
|
-
|
704
|
Inventory
impairment
|
|
1,459
|
1,778
|
|
2,132
|
6,656
|
Gross profit/(loss)
excluding fair value items
|
|
4,496
|
4,983
|
|
12,766
|
4,505
|
|
|
|
|
|
|
|
Unrealized fair value
gain/(loss) on biological transformation
|
|
4,713
|
11,735
|
|
8,960
|
18,208
|
Realized fair value
gain/(loss) on inventory
|
|
(3,146)
|
(6,898)
|
|
(7,785)
|
(9,223)
|
Gross
profit
|
|
6,063
|
9,820
|
|
13,941
|
13,490
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
Selling, general, and
administrative expenses
|
|
8,810
|
12,936
|
|
18,900
|
25,575
|
Equity-based
compensation
|
|
377
|
2,916
|
|
786
|
3,119
|
Depreciation and
amortization
|
|
1,673
|
3,900
|
|
3,418
|
8,500
|
Interest and accretion
expense
|
|
6,457
|
5,336
|
|
12,265
|
10,416
|
Total
expenses
|
|
17,317
|
25,088
|
|
35,369
|
47,610
|
|
|
|
|
|
|
|
Other
income/(loss)
|
|
|
|
|
|
|
Interest and other
income
|
|
(20)
|
84
|
|
(6)
|
169
|
Impairment of
assets
|
|
(2,588)
|
-
|
|
(2,588)
|
(23,673)
|
Gain/(loss) on
settlement of assets and liabilities and other expenses
|
|
1,478
|
(1,987)
|
|
1,478
|
(1,987)
|
Gain on disposal of
assets held for sale
|
|
-
|
2,150
|
|
-
|
2,150
|
Foreign exchange
gain/(loss)
|
|
(479)
|
647
|
|
(568)
|
286
|
Total other
income/(loss)
|
|
(1,609)
|
894
|
|
(1,684)
|
(23,055)
|
|
|
|
|
|
|
|
Net loss before
income tax
|
|
(12,863)
|
(14,374)
|
|
(23,112)
|
(57,175)
|
Income tax
recovery
|
|
-
|
85
|
|
-
|
3,040
|
Net
income/(loss)
|
|
$
(12,863)
|
$
(14,289)
|
|
$
(23,112)
|
$
(54,135)
|
|
|
|
|
|
|
|
Adjusted
EBITDA
|
|
$
(1,078)
|
$
(3,995)
|
|
$
(940)
|
$
(10,319)
|
|
|
|
|
|
|
|
Net income/(loss)
per common share (basic and diluted)
|
|
$
(0.01)
|
$
(0.02)
|
|
$
(0.02)
|
$
(0.06)
|
|
|
|
|
|
|
|
Weighted average
shares outstanding (basic and diluted)
|
|
1,002,014,308
|
888,266,729
|
|
978,146,905
|
875,843,490
|
Hugo Alves, CEO of Auxly, commented: "The results for the
second quarter of 2023 reflect our focus on simplifying and
streamlining the business to improve operating efficiency and
reduce costs. We have successfully consolidated our dried flower
and pre-roll cannabis product manufacturing, processing and
distribution activities, which was a key strategic goal for this
year. While the transition had a temporary impact on the sales and
financial performance during the quarter, we have already observed
a positive impact of increased product throughput and improved
product quality as a result of this consolidation. This is a part
of a broader strategy to ensure Auxly can remain competitive
against a backdrop of continued price compression and
disproportionate taxation in the adult use recreational market. We
believe that Auxly is well-positioned to compete in the current
value-price driven environment given our brand portfolio, Auxly
Leamington's cost structure and the automation investments we have
made to our manufacturing processes. We remain focused on our key
product categories of dried flower, pre-rolls and vape and will
continue to introduce exciting new products across those product
formats to satisfy our consumers' evolving preferences."
Net Revenues
For the three and six months ended June
30, 2023, net revenues were $22.0
million and $46.0 million as
compared to $27.3 million and
$50.0 million during the same period
in 2022, a decline of 20% and 8% respectively. Revenues for the
three and six months ended June 30,
2023 were comprised of approximately 50% in sales of dried
flower and pre-roll Cannabis Products, with the remainder from oils
and Cannabis 2.0 Product sales. Net revenues included
wholesale bulk flower sales of approximately $1.9 million and $2.9
million during the three and six months ended June 30, 2023. Auxly maintained its position as a
top 5 LP, by maintaining strength in sales of both Cannabis 1.0 and
Cannabis 2.0 Products.
Consistent with prior periods, as the Company does not
participate in the Quebec market,
approximately 85% of cannabis sales during the period originated
from sales to British Columbia,
Alberta and Ontario.
Gross Profit
Auxly realized a gross profit of $6.1
million and $13.9 million for
the three and six months ending June 30,
2023 resulting in a 28% and 30% Gross Profit Margin
respectively, as compared to $9.8
million (36%) and $13.5
million (27%) during the same periods in 2022. Excluding
non-cash amounts, the Cost of Finished Cannabis Inventory Sold
Margin for the three months ended June 30,
2023 improved to 27% versus 25% in the same period of 2022.
This is primarily as a result of a higher proportion of Cannabis
1.0 Products sold by the Company utilizing low-cost cannabis
cultivated at Auxly Leamington, and the streamlining of certain
Cannabis Products and operating costs.
Realized and unrealized fair value gains and losses reflect
accounting treatments associated with Auxly Leamington cultivation
activities and sales and are influenced by changes in production,
sales and net realizable value assumptions.
Inventory impairments during the second quarter of 2023 of
$1.5 million were associated with
certain slower moving SKUs and certain product not meeting quality
specifications, a reduction of $0.3
million from the comparative period. The impairments
recognized in the six months ending June 30,
2022 include impairments related to the closure of the Auxly
Annapolis facilities.
Total Expenses
Selling, general and administrative expenses ("SG&A") are
comprised of wages and benefits, office and administrative,
professional fees, business development, and selling expenses.
SG&A expenses were $8.8 million
during the second quarter of 2023, $4.1
million lower than the second quarter of 2022 primarily due
to lower wages and benefits and selling expenses. Year-to-date
expenditures of $18.9 million in 2023
are $6.7 million lower than the same
period in 2022 primarily due to measures taken to reduce overhead
in the organization and lower selling expenditures.
Wages and benefits were $3.3
million for the second quarter of 2023, as compared to
$5.1 million for the same period of
2022. The decrease in expenses was related to the streamlining of
operations and support staff for a more focused product portfolio
and adjustments to compensation accruals. Year-to-date expenditures
of $8.0 million were lower than those
of $10.7 million during the same
period of 2022. The decrease is primarily due to measures taken
after the third quarter of 2022 to reduce overhead in the
organization.
Office and administrative expenses were $3.1 million for the period ended June 30, 2023, increasing by $0.6 million compared to the same period in 2022.
The increased expenditures primarily relate to a provision for bad
debt related to Fire & Flower Holdings Corp. filing for
creditor protection under the Companies' Creditors Arrangement Act
and the timing and costs associated with product innovation.
Auxly's professional fees were $0.6
million during the second quarter of 2023 and $1.4 million year-to-date which was $0.5 million and $0.1
million lower than the same periods in 2022. Professional
fees incurred primarily related to accounting fees, regulatory
matters, reporting issuer fees, and legal fees associated with
certain corporate activities and as a result can fluctuate
significantly from one period to the next.
Business development expenses were $0.2
million for the three and six months ended June 30, 2023 as compared to $0.1 million and $0.2
million during the same periods in 2022. These expenses
primarily relate to acquisition, business development and travel
related expenses.
Selling expenses were $1.6 million
for the three months ended June 30,
2023 and $3.9 million
year-to-date, decreases of $2.5
million and $3.1 million over
the same periods in 2022, primarily as a result of cost reductions
associated with the internalization of the sales team, lower Health
Canada fees related to lower revenues, and reduced marketing
initiatives.
Equity-based compensation for the three and six months ended
June 30, 2023 was $0.4 million and $0.8
million respectively. During the same periods of 2022, these
amounts were $2.9 million and
$3.1 million, primarily reflecting
the impact of restricted share units ("RSU") granted in
June 2022, in respect of services
provided by employees in 2021.
Depreciation and amortization expenses were $1.7 million for the period ended June 30, 2023, and $3.4
million year-to-date decreasing by $2.2 million and $5.1
million respectively over the same periods in 2022,
primarily as a result of reductions in intangible assets,
completion of certain leases and right of use assets, and
depreciation associated with disposed assets.
Interest expenses were $6.5
million and $12.3 million for
the three and six months ended June 30,
2023, an increase of $1.1
million and $1.8 million over
the same periods in 2022. The increase in expense is primarily a
result of the impact of rising interest rates where such
obligations are subject to variable charges. Interest expense
includes accretion on the convertible debentures and interest paid
in kind on the $123 million Imperial
Brands Debenture. Interest payable in cash was approximately
$2.6 million for the three month
ended June 30, 2023, an increase of
$0.9 million over the same period in
2022.
Total Other Incomes and Losses
Total other incomes and losses for the second quarter of 2023
was a net loss of $1.6 million
primarily related to the closure of the Auxly Ottawa facility where
the carrying value exceeded the fair value less cost to sell,
partially offset by gains due to extensions on unsecured promissory
notes. Total other income in the second quarter of 2022 was
$0.9 million primarily resulting from
the gains related to the sale of Auxly Annapolis and the extension
of the unsecured convertible debentures partially offset by other
losses.
Total other incomes and losses for the six months ending
June 30, 2023 was a net loss of
$1.7 million compared to a net loss
of $23.1 million in the comparative
period, which included first quarter losses associated with the
closure of the Auxly Annapolis and Auxly Annapolis OG
facilities.
Net Income and Loss
Net losses for the three months ended June 30, 2023 were $12.9
million, representing a net loss of $0.01 per share on a basic and diluted basis. The
change in net loss in the second quarter of 2023 as compared to the
same period of 2022 was primarily driven by changes in total
expenses and reduced gross profits. The net loss of $54.1 million through six months of 2022 includes
the net impact of approximately $25.7
million related to the closure of the Auxly Annapolis and
Auxly Annapolis OG facilities during the first quarter of 2022.
Adjusted EBITDA
Adjusted EBITDA for the three months ended June 30, 2023 was negative $1.1 million, an improvement of $2.9 million over the same period of 2022,
primarily as a result of improvements in SG&A partially offset
by lower net revenues and increased costs of finished cannabis
inventory sold.
Outlook
In 2023, we aim to continue to improve earnings performance,
increase focus on key product formats, lower costs and increase
efficiency, which we expect will yield positive results. With these
actions in mind, our goals for 2023 are broadly defined below:
- Increase net revenues by 15%, with a focus on key product
categories, enhanced by strategic expansion of our product
portfolio, while supporting strong retail distribution through our
internal sales team.
- Continue to leverage Auxly Leamington's large-scale, low-cost
cultivation facility and the Company's manufacturing automation to
increase blended Cost of Finished Cannabis Inventory Sold Margin to
an average of 35-40%.
- Vigorously manage SG&A as a percentage of net revenues to
keep it below 40%, further building upon savings realized in Q4
2022.
- Prudently manage the Company's balance sheet and streamline
assets where possible.
In the second quarter of 2023, the Company continued to focus on
simplifying and streamlining its business to improve operating
efficiency and reduce costs. The Company successfully transitioned
all functions previously conducted at its Auxly Ottawa facility to
its Auxly Leamington facility, and is in the process of winding
down and disposing of Auxly Ottawa's assets. While the transition
had a temporary impact on the Company's sales and financial
performance during the quarter, it allowed the Company to better
tailor its workforce and operations and has resulted in increased
throughput and product quality which the Company believes will
improve its pre-roll and dried flower product category performance
in the near term. The results for the second quarter of 2023 were
also negatively impacted by price compression in the adult-use
recreational market as the customer and product mix evolved to
focus more on value offerings, and by increased competition in the
value price segment, particularly in the 28 gram dried flower
format. The Company believes that it is well-positioned to compete
in the value price segment given its brand portfolio and Auxly
Leamington's cost structure and has taken steps to adjust existing
product pricing where necessary and increase distribution for its
Parcel branded products. Despite lower sales and gross profits in
the second quarter compared to the first quarter, the Company made
material improvements in its SG&A by reducing overhead in the
organization and will continue to actively manage spending while
looking for further cost reduction opportunities.
Non-GAAP Measures
Please see the Company's MD&A for the three months and six
months ended June 30, 2023, under
"Non-GAAP Measures" for a further description of the following
financial and supplementary financial measures.
Financial Measures
EBITDA and Adjusted EBITDA
These are non-GAAP measures used in the cannabis industry and by
the Company to assess operating performance removing the impacts
and volatility of non-cash adjustments. The definition may differ
by issuer. The Adjusted EBITDA reconciliation is as follows:
(000's)
|
|
Q2/23
|
Q1/23
|
Q4/22
|
Q3/22
|
Q2/22
|
Q1/22
|
Q4/21
|
Q3/21
|
Net
income/(loss)
|
|
$
(12,863)
|
$
(10,249)
|
$
(16,056)
|
$
(60,102)
|
$
(14,289)
|
$
(39,846)
|
$
(18,376)
|
$
(13,527)
|
Interest and accretion
expense
|
|
6,457
|
5,808
|
5,655
|
5,507
|
5,336
|
5,080
|
4,348
|
3,932
|
Interest
income
|
|
20
|
(14)
|
(63)
|
(105)
|
(84)
|
(85)
|
(308)
|
(436)
|
Income tax
recovery
|
|
-
|
-
|
(1,112)
|
(2,110)
|
(85)
|
(2,955)
|
-
|
-
|
Depreciation and
amortization
included in cost of sales
|
|
911
|
1,120
|
1,296
|
681
|
2,180
|
1,211
|
689
|
386
|
Depreciation and
amortization
included in expenses
|
|
1,673
|
1,745
|
2,791
|
3,525
|
3,900
|
4,600
|
5,678
|
2,223
|
EBITDA
|
|
(3,802)
|
(1,590)
|
(7,489)
|
(52,604)
|
(3,042)
|
(31,995)
|
(7,969)
|
(7,422)
|
|
|
|
|
|
|
|
|
|
|
Impairment of
biological
assets
|
|
-
|
-
|
-
|
-
|
-
|
704
|
-
|
-
|
Impairment of
inventory
|
|
1,459
|
673
|
2,062
|
2,014
|
1,778
|
4,878
|
2,194
|
716
|
Unrealized fair value
loss /
(gain) on
biological transformation
|
|
(4,713)
|
(4,247)
|
(2,814)
|
(7,496)
|
(11,735)
|
(6,473)
|
(1,462)
|
(352)
|
Realized fair value
loss /
(gain) on inventory
|
|
3,146
|
4,639
|
7,382
|
8,175
|
6,898
|
2,325
|
904
|
1
|
Restructuring related
costs
|
|
86
|
165
|
-
|
193
|
-
|
-
|
-
|
-
|
Equity-based
compensation
|
|
377
|
409
|
429
|
475
|
2,916
|
203
|
212
|
55
|
Fair value loss /
(gain) for
financial
instruments accounted
under FVTPL
|
|
-
|
-
|
-
|
-
|
-
|
-
|
408
|
(223)
|
Impairment of
assets
|
|
2,588
|
-
|
676
|
42,831
|
-
|
23,673
|
-
|
60
|
Non-recurring bad
debt
expense
|
|
780
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(Gain) / loss on
settlement
of assets,
liabilities and disposals
|
|
(1,478)
|
-
|
(1,330)
|
1,574
|
(163)
|
-
|
815
|
(1,396)
|
Share of loss on
investment
in joint venture
|
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,387)
|
3,095
|
Foreign exchange loss
/
(gain)
|
|
479
|
89
|
301
|
(938)
|
(647)
|
361
|
242
|
(633)
|
Adjusted
EBITDA
|
|
$
(1,078)
|
$
138
|
$ (783)
|
$
(5,776)
|
$
(3,995)
|
$
(6,324)
|
$
(6,043)
|
$
(6,099)
|
Supplementary Financial Measures
Cost of Finished Cannabis Inventory Sold
Margin
"Cost of Finished Cannabis Inventory Sold Margin" is a
supplementary financial measure and is defined as Cost of Finished
Cannabis Inventory Sold divided by net revenues.
Gross Profit Margin
"Gross Profit Margin" is defined as gross profit divided by net
revenues. Gross Profit Margin is a supplementary financial
measure.
Debt
"Debt" is defined as current and long-term debt and is a
supplementary financial measure. It is a useful measure in managing
our capital structure and financing requirements.
Conference Call
The Company will not host an earnings conference call and the
Company does not anticipate reinstating earnings conference calls
until further notice. All investor inquiries should be directed to
IR@auxly.com.
ON BEHALF OF THE BOARD
"Hugo Alves" CEO
About Auxly Cannabis Group Inc. (TSX: XLY)
Auxly is a leading Canadian consumer packaged goods company in
the cannabis products market, headquartered in Toronto, Canada. Our focus is on developing,
manufacturing and distributing branded cannabis products that
delight our consumers.
Our vision is to be a leader in branded cannabis products that
deliver on our consumer promise of quality, safety and
efficacy.
Learn more at www.auxly.com and stay up to date at Twitter:
@AuxlyGroup; Instagram: @auxlygroup; Facebook:
@auxlygroup; LinkedIn: company/auxlygroup/.
Notice Regarding Forward Looking Information:
This news release contains certain "forward-looking information"
within the meaning of applicable Canadian securities law.
Forward-looking information is frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or information that certain
events or conditions "may" or "will" occur. This information is
only a prediction. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking information throughout this news release.
Forward-looking information includes, but is not limited to: the
proposed operation of Auxly and its subsidiaries; the intention to
grow the business, operations and existing and
potential activities of Auxly; the Company's execution of its
innovative product development, commercialization strategy and
expansion plans; the Company's intention to introduce innovative
new cannabis products to the market and the timing thereof; the
anticipated benefits of the Company's partnerships, research and
development initiatives and other commercial arrangements; the
current and anticipated benefits of the Company's acquisition of
Auxly Leamington; the intention of the Company to sell the Auxly
Ottawa assets and the proposed use of any proceeds; the intention
of the Company to sell the Auxly Ottawa assets and the proposed use
of any proceeds; the expectation, timing and quantum of future
revenues, Cost of Finished Cannabis Inventory Sold Margin, SG&A
and of positive Adjusted EBITDA; expectations regarding
the Company's expansion of sales, operations and investment
into foreign jurisdictions; future legislative and regulatory
developments involving cannabis and cannabis products; the timing
and outcomes of regulatory or intellectual property decisions; the
relevance of Auxly's subsidiaries' current and proposed products
with provincial purchasers and consumers; consumer preferences;
political change; competition and other risks affecting the Company
in particular and the cannabis industry generally.
A number of factors could cause actual results to differ
materially from a conclusion, forecast or projection contained in
the forward-looking information in this release including, but not
limited to, whether: the Company will be able to execute on
its business strategy or achieve its goals; Auxly's subsidiaries
are able to obtain and maintain the necessary governmental and
regulatory authorizations to conduct business; the Company is able
to successfully manage the integration of its various business
units with its own; there are
not materially more closures or lockdowns related
to the COVID‐19 pandemic; the Company's subsidiaries
obtain and maintain all necessary governmental and regulatory
permits and approvals for the operation of their facilities and the
development of cannabis products, and whether such permits and
approvals can be obtained in a timely manner; the Company will be
able to continue to successfully integrate Auxly Leamington's
operations with its own, and whether the expected benefits of the
acquisition materialize in the manner expected, or at all; the
Company will be able to sell the Auxly Ottawa assets and achieve
the anticipated cost savings from the closure of the
facility; the Company is able to implement the Imperial Brands
Debenture amendment on the proposed timeline, and whether the
expected benefits of the amendment materialize in the manner
expected, or at all; the Company will be able to sell the Auxly
Ottawa assets and achieve the anticipated cost savings from the
closure of the facility; the Company will be able to successfully
launch new product formats and enter into new markets; there is
acceptance and demand for current and future Company products by
consumers and provincial purchasers; the Company will be able to
increase and maintain revenues, maintain positive Adjusted EBITDA,
and/or achieve and maintain its target Cost of Finished Cannabis
Inventory Sold Margin; and general economic, financial market,
legislative, regulatory, competitive and political conditions in
which the Company and its subsidiaries and partners operate will
remain the same. Additional risk factors are disclosed in the
annual information form of the Company for the financial year ended
December 31, 2022 dated March 30, 2023.
New factors emerge from time to time, and it is not possible for
management to predict all of those factors or to assess in advance
the impact of each such factor on the Company's business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking information. The forward-looking information in
this release is based on information currently available and what
management believes are reasonable assumptions. Forward-looking
information speaks only to such assumptions as of the date of this
release. In addition, this release may contain forward-looking
information attributed to third party industry sources, the
accuracy of which has not been verified by the Company. The
forward-looking information is being provided for the purposes of
assisting the reader in understanding the Company's financial
performance, financial position and cash flows as at and for
periods ended on certain dates and to present information about
management's current expectations and plans relating to the future,
and the reader is cautioned that such forward-looking information
may not be appropriate for any other purpose. Readers should not
place undue reliance on forward-looking information contained in
this release.
The forward-looking information contained in this release is
expressly qualified by the foregoing cautionary statements and is
made as of the date of this release. Except as may be required by
applicable securities laws, the Company does not undertake any
obligation to publicly update or revise any forward-looking
information to reflect events or circumstances after the date of
this release or to reflect the occurrence of unanticipated events,
whether as a result of new information, future events or results,
or otherwise.
Neither Toronto Stock Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the Toronto
Stock Exchange) accepts responsibility for the adequacy or accuracy
of this release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/auxly-reports-q2-2023-financial-results-301899559.html
SOURCE Auxly Cannabis Group Inc.